Abstract |
Ultimately aiming at a more individualized therapeutic approach in epidermoid anal cancer, this study explored the prognostic and predictive impact of a set of tumour markers. From a population-based cohort of 276 patients with epidermoid anal cancer, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry. The expression of p53, p21, Cyclin A and CD31 was measured semi-quantitatively. The expression rate was classified as high when immunostaining was seen in > 5% of the tumour cells for p53 and p21, > 20% in Cyclin A and, above median vessel count for CD31. Marker expression was correlated to survival and treatment response. A high Cyclin A expression correlated significantly with improved overall (77% vs 59%, p = 0.005) and tumour-specific (81% vs 64%, p = 0.009) survival at 5 years. Also, the locoregional failure rate was significantly lower in patients with a high Cyclin A expression (12% vs 24%, p < 0.05). In a multivariate Cox analysis Cyclin A was an independent prognostic factor. A low p21 expression correlated with a reduced rate of locoregional failure (14% vs 27%, p < 0.05) but no impact on survival was found. For p53 and CD31 no significant correlations were obtained. Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in epidermoid anal cancer.
|
Authors | Per J Nilsson, Claes Lenander, Carlos Rubio, Gert Auer, Olle Ljungqvist, Bengt Glimelius |
Journal | Oncology reports
(Oncol Rep)
Vol. 16
Issue 3
Pg. 443-9
(Sep 2006)
ISSN: 1021-335X [Print] Greece |
PMID | 16865241
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- CDKN1A protein, human
- Cyclin A
- Cyclin-Dependent Kinase Inhibitor p21
- Platelet Endothelial Cell Adhesion Molecule-1
- Tumor Suppressor Protein p53
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Anus Neoplasms
(metabolism, mortality, therapy)
- Biomarkers, Tumor
(metabolism)
- Carcinoma, Squamous Cell
(metabolism, mortality, therapy)
- Cohort Studies
- Cyclin A
(metabolism)
- Cyclin-Dependent Kinase Inhibitor p21
(metabolism)
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Platelet Endothelial Cell Adhesion Molecule-1
(metabolism)
- Prospective Studies
- Survival Rate
- Treatment Outcome
- Tumor Suppressor Protein p53
(metabolism)
|